These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37228094)

  • 1. Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C.
    Chi SN; Yi JS; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey BD; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga JC; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Natl Cancer Inst; 2023 Nov; 115(11):1355-1363. PubMed ID: 37228094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study.
    Gounder M; Schöffski P; Jones RL; Agulnik M; Cote GM; Villalobos VM; Attia S; Chugh R; Chen TW; Jahan T; Loggers ET; Gupta A; Italiano A; Demetri GD; Ratan R; Davis LE; Mir O; Dileo P; Van Tine BA; Pressey JG; Lingaraj T; Rajarethinam A; Sierra L; Agarwal S; Stacchiotti S
    Lancet Oncol; 2020 Nov; 21(11):1423-1432. PubMed ID: 33035459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases.
    Holdhof D; Johann PD; Spohn M; Bockmayr M; Safaei S; Joshi P; Masliah-Planchon J; Ho B; Andrianteranagna M; Bourdeaut F; Huang A; Kool M; Upadhyaya SA; Bendel AE; Indenbirken D; Foulkes WD; Bush JW; Creytens D; Kordes U; Frühwald MC; Hasselblatt M; Schüller U
    Acta Neuropathol; 2021 Feb; 141(2):291-301. PubMed ID: 33331994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
    Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
    Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tazemetostat in the therapy of pediatric INI1-negative malignant rhabdoid tumors.
    Vejmelkova K; Pokorna P; Noskova K; Faustmannova A; Drabova K; Pavelka Z; Bajciova V; Broz M; Tinka P; Jezova M; Palova H; Kren L; Valik D; Slaby O; Sterba J
    Sci Rep; 2023 Dec; 13(1):21623. PubMed ID: 38062114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan.
    Izutsu K; Ando K; Nishikori M; Shibayama H; Teshima T; Kuroda J; Kato K; Imaizumi Y; Nosaka K; Sakai R; Hojo S; Nakanishi T; Rai S
    Cancer Sci; 2021 Sep; 112(9):3627-3635. PubMed ID: 34159682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial.
    Eckstein OS; Allen CE; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Ramirez NC; Jaju A; Mhlanga J; Fox E; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    J Clin Oncol; 2022 Jul; 40(20):2235-2245. PubMed ID: 35363510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study.
    Zauderer MG; Szlosarek PW; Le Moulec S; Popat S; Taylor P; Planchard D; Scherpereel A; Koczywas M; Forster M; Cameron RB; Peikert T; Argon EK; Michaud NR; Szanto A; Yang J; Chen Y; Kansra V; Agarwal S; Fennell DA
    Lancet Oncol; 2022 Jun; 23(6):758-767. PubMed ID: 35588752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial.
    Morschhauser F; Tilly H; Chaidos A; McKay P; Phillips T; Assouline S; Batlevi CL; Campbell P; Ribrag V; Damaj GL; Dickinson M; Jurczak W; Kazmierczak M; Opat S; Radford J; Schmitt A; Yang J; Whalen J; Agarwal S; Adib D; Salles G
    Lancet Oncol; 2020 Nov; 21(11):1433-1442. PubMed ID: 33035457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical teratoid/rhabdoid tumor with retained INI1 (SMARCB1) expression and loss of BRG1 (SMARCA4).
    Bookhout C; Bouldin TW; Ellison DW
    Neuropathology; 2018 Jun; 38(3):305-308. PubMed ID: 29271065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdoid tumor predisposition syndrome.
    Sredni ST; Tomita T
    Pediatr Dev Pathol; 2015; 18(1):49-58. PubMed ID: 25494491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SMARCB1-deficient and SMARCA4-deficient Malignant Brain Tumors With Complex Copy Number Alterations and TP53 Mutations May Represent the First Clinical Manifestation of Li-Fraumeni Syndrome.
    Hasselblatt M; Thomas C; Federico A; Nemes K; Johann PD; Bison B; Bens S; Dahlum S; Kordes U; Redlich A; Lessel L; Pajtler KW; Mawrin C; Schüller U; Nolte K; Kramm CM; Hinz F; Sahm F; Giannini C; Penkert J; Kratz CP; Pfister SM; Siebert R; Paulus W; Kool M; Frühwald MC
    Am J Surg Pathol; 2022 Sep; 46(9):1277-1283. PubMed ID: 35446794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
    Pawel BR
    Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome.
    Foulkes WD; Kamihara J; Evans DGR; Brugières L; Bourdeaut F; Molenaar JJ; Walsh MF; Brodeur GM; Diller L
    Clin Cancer Res; 2017 Jun; 23(12):e62-e67. PubMed ID: 28620006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epithelioid Sarcoma Arising in a Long-Term Survivor of an Atypical Teratoid/Rhabdoid Tumor in a Patient With Rhabdoid Tumor Predisposition Syndrome.
    Baker TG; Lyons MJ; Leddy L; Parham DM; Welsh CT
    Pediatr Dev Pathol; 2021; 24(2):164-168. PubMed ID: 33470921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.
    Vo KT; Sabnis AJ; Williams PM; Roy-Chowdhuri S; Patton DR; Coffey B; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Jaju A; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    JCO Precis Oncol; 2024 Jun; 8():e2400103. PubMed ID: 38935895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma.
    Munakata W; Shirasugi Y; Tobinai K; Onizuka M; Makita S; Suzuki R; Maruyama D; Kawai H; Izutsu K; Nakanishi T; Shiba S; Hojo S; Ando K
    Cancer Sci; 2021 Mar; 112(3):1123-1131. PubMed ID: 33492746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of BRG1 (
    Saunders J; Ingley K; Wang XQ; Harvey M; Armstrong L; Ng T; Dunham C; Bush J
    Pediatr Dev Pathol; 2020; 23(2):132-138. PubMed ID: 31403913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I).
    Macy ME; Mody R; Reid JM; Piao J; Saguilig L; Alonzo TA; Berg SL; Fox E; Weigel BJ; Hawkins DS; Mooney MM; Williams PM; Patton DR; Coffey BD; Roy-Chowdhuri S; Takebe N; Tricoli JV; Janeway KA; Seibel NL; Parsons DW
    JCO Precis Oncol; 2024 Sep; 8():e2400418. PubMed ID: 39298716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.